Crinetics Pharmaceuticals (CRNX) Stock Forecast, Price Target & Predictions
CRNX Stock Forecast
Crinetics Pharmaceuticals stock forecast is as follows: an average price target of $70.14 (represents a 30.37% upside from CRNX’s last price of $53.80) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
CRNX Price Target
The average price target for Crinetics Pharmaceuticals (CRNX) is $70.14 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $97.00 to $39.00. This represents a potential 30.37% upside from CRNX's last price of $53.80.
CRNX Analyst Ratings
According to 6 Wall Street analysts, Crinetics Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for CRNX stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Crinetics Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 09, 2024 | Douglas Tsao | H.C. Wainwright | $69.00 | $50.74 | 35.99% | 28.25% |
| Jun 04, 2024 | Leland Gershell | Oppenheimer | $74.00 | $46.28 | 59.90% | 37.55% |
| May 23, 2024 | Brian Skorney | Robert W. Baird | $62.00 | $49.13 | 26.20% | 15.24% |
| May 22, 2024 | Jeffrey Hung | Morgan Stanley | $70.00 | $50.54 | 38.50% | 30.11% |
| May 07, 2024 | Yasmeen Rahimi | Piper Sandler | $97.00 | $47.47 | 104.34% | 80.30% |
| Mar 20, 2024 | Jonathan Wolleben | JMP Securities | $80.00 | $45.49 | 75.86% | 48.70% |
| Mar 13, 2024 | Leland Gershell | Oppenheimer | $54.00 | $40.50 | 33.33% | 0.37% |
| Aug 31, 2023 | Leland Gershell | Oppenheimer | $40.00 | $17.43 | 129.49% | -25.65% |
| May 26, 2022 | - | Leerink Partners | $39.00 | $17.37 | 124.53% | -27.51% |
The latest Crinetics Pharmaceuticals stock forecast, released on Aug 09, 2024 by Douglas Tsao from H.C. Wainwright, set a price target of $69.00, which represents a 35.99% increase from the stock price at the time of the forecast ($50.74), and a 28.25% increase from CRNX last price ($53.80).
Crinetics Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 7 |
| Avg Price Target | - | $69.00 | $72.29 |
| Last Closing Price | $53.80 | $53.80 | $53.80 |
| Upside/Downside | -100.00% | 28.25% | 34.37% |
In the current month, the average price target of Crinetics Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Crinetics Pharmaceuticals's last price of $53.80. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 09, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 02, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 28, 2024 | Oppenheimer | Underperform | Underperform | Hold |
| Jun 28, 2024 | Piper Sandler | Market Outperform | Market Outperform | Hold |
| Jun 04, 2024 | Piper Sandler | Buy | Buy | Hold |
| Jun 04, 2024 | Oppenheimer | Underperform | Underperform | Hold |
| Jun 04, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 04, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 23, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| May 22, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
Crinetics Pharmaceuticals's last stock rating was published by H.C. Wainwright on Aug 09, 2024. The company gave CRNX a "Buy" rating, the same as its previous rate.
Crinetics Pharmaceuticals Financial Forecast
Crinetics Pharmaceuticals Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $988.00K | $2.68M | $709.00K | $458.00K | $439.00K | $3.13M | $71.00K | $321.00K | $505.00K | - | $367.00K | $657.00K |
| Avg Forecast | $15.00M | $12.00M | $7.50M | $5.00M | $4.15M | $544.57K | $460.86K | $71.29K | $672.64K | $218.09K | $467.27K | $200.00K | $197.10K | $1.10M | $254.25K | $250.00K | $250.00K | $600.00K | $5.20M | $63.00K | $130.00K | $150.00K | $187.50K | $130.00K | $3.73M |
| High Forecast | $15.00M | $12.00M | $7.50M | $5.00M | $4.15M | $544.57K | $460.86K | $71.29K | $672.64K | $275.75K | $467.27K | $200.00K | $307.97K | $1.10M | $254.25K | $250.00K | $250.00K | $758.62K | $6.57M | $75.60K | $164.37K | $189.66K | $237.07K | $164.37K | $4.48M |
| Low Forecast | $15.00M | $12.00M | $7.50M | $5.00M | $4.15M | $544.57K | $460.86K | $71.29K | $672.64K | $157.93K | $467.27K | $200.00K | $92.39K | $1.10M | $254.25K | $250.00K | $250.00K | $434.48K | $3.77M | $50.40K | $94.14K | $108.62K | $135.78K | $94.14K | $2.99M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 7 | 4 | 3 | 13 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.90% | 10.54% | 2.84% | 1.83% | 0.73% | 0.60% | 1.13% | 2.47% | 3.37% | - | 2.82% | 0.18% |
Crinetics Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 6 analysts is $197.10K, with a low forecast of $92.39K, and a high forecast of $307.97K. CRNX's average Quarter revenue forecast represents a -80.05% decrease compared to the company's last Quarter revenue of $988.00K (Jun 23).
Crinetics Pharmaceuticals EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 7 | 4 | 3 | 13 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-52.72M | $-47.98M | $-47.56M | $-43.21M | $-42.86M | $-33.59M | $-17.13M | $-14.32M | $-14.20M | $-12.25M | $-8.76M | $-5.49M |
| Avg Forecast | $-15.00M | $-12.00M | $-7.50M | $-5.00M | $-4.15M | $-544.57K | $-460.86K | $-71.29K | $-672.64K | $-218.09K | $-467.27K | $-200.00K | $-197.10K | $-1.10M | $-254.25K | $-250.00K | $-250.00K | $-600.00K | $-25.35M | $-14.95M | $-130.00K | $-150.00K | $-187.50K | $-9.62M | $-31.19M |
| High Forecast | $-15.00M | $-12.00M | $-7.50M | $-5.00M | $-4.15M | $-544.57K | $-460.86K | $-71.29K | $-672.64K | $-157.93K | $-467.27K | $-200.00K | $-92.39K | $-1.10M | $-254.25K | $-250.00K | $-250.00K | $-434.48K | $-20.28M | $-11.96M | $-94.14K | $-108.62K | $-135.78K | $-7.69M | $-24.95M |
| Low Forecast | $-15.00M | $-12.00M | $-7.50M | $-5.00M | $-4.15M | $-544.57K | $-460.86K | $-71.29K | $-672.64K | $-275.75K | $-467.27K | $-200.00K | $-307.97K | $-1.10M | $-254.25K | $-250.00K | $-250.00K | $-758.62K | $-30.42M | $-17.94M | $-164.37K | $-189.66K | $-237.07K | $-11.54M | $-37.43M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 48.05% | 188.70% | 190.22% | 172.82% | 71.44% | 1.32% | 1.15% | 110.15% | 94.68% | 65.33% | 0.91% | 0.18% |
undefined analysts predict CRNX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Crinetics Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Crinetics Pharmaceuticals Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 7 | 4 | 3 | 13 | 15 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-50.98M | $-44.01M | $-42.43M | $-40.40M | $-41.70M | $-35.43M | $-17.36M | $-14.55M | $-14.43M | $-12.43M | $-9.02M | $-5.57M |
| Avg Forecast | $-90.86M | $-90.86M | $-90.86M | $-89.28M | $-84.24M | $-83.65M | $-78.81M | $-75.55M | $-73.43M | $-71.95M | $-67.86M | $-63.96M | $-68.15M | $-68.39M | $-65.20M | $-65.01M | $-61.99M | $-50.68M | $-25.67M | $-15.16M | $-53.46M | $-44.88M | $-36.03M | $-9.90M | $-31.62M |
| High Forecast | $-90.86M | $-90.86M | $-90.86M | $-89.28M | $-84.24M | $-83.65M | $-78.81M | $-75.55M | $-73.43M | $-67.21M | $-67.86M | $-63.96M | $-62.02M | $-68.39M | $-65.20M | $-65.01M | $-61.99M | $-32.50M | $-20.54M | $-12.12M | $-34.29M | $-28.78M | $-23.11M | $-7.92M | $-25.30M |
| Low Forecast | $-90.86M | $-90.86M | $-90.86M | $-89.28M | $-84.24M | $-83.65M | $-78.81M | $-75.55M | $-73.43M | $-75.90M | $-67.86M | $-63.96M | $-76.57M | $-68.39M | $-65.20M | $-65.01M | $-61.99M | $-68.10M | $-30.81M | $-18.19M | $-71.84M | $-60.30M | $-48.41M | $-11.87M | $-37.95M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.75% | 0.68% | 0.65% | 0.65% | 0.82% | 1.38% | 1.15% | 0.27% | 0.32% | 0.34% | 0.91% | 0.18% |
Crinetics Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CRNX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Crinetics Pharmaceuticals SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 7 | 4 | 3 | 13 | 15 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $13.34M | $12.19M | $11.27M | $11.93M | $10.49M | $8.71M | $3.99M | $3.39M | $3.91M | $3.06M | $3.16M | $1.12M |
| Avg Forecast | $934.19M | $747.35M | $467.09M | $311.40M | $258.61M | $33.92M | $28.70M | $4.44M | $41.89M | $13.58M | $29.10M | $12.46M | $12.28M | $68.32M | $15.83M | $15.57M | $15.57M | $37.37M | $323.85M | $3.92M | $8.10M | $9.34M | $11.68M | $8.10M | $232.38M |
| High Forecast | $934.19M | $747.35M | $467.09M | $311.40M | $258.61M | $33.92M | $28.70M | $4.44M | $41.89M | $17.17M | $29.10M | $12.46M | $19.18M | $68.32M | $15.83M | $15.57M | $15.57M | $47.25M | $409.47M | $4.71M | $10.24M | $11.81M | $14.76M | $10.24M | $278.86M |
| Low Forecast | $934.19M | $747.35M | $467.09M | $311.40M | $258.61M | $33.92M | $28.70M | $4.44M | $41.89M | $9.84M | $29.10M | $12.46M | $5.75M | $68.32M | $15.83M | $15.57M | $15.57M | $27.06M | $234.51M | $3.14M | $5.86M | $6.76M | $8.46M | $5.86M | $185.91M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.20% | 0.77% | 0.72% | 0.77% | 0.28% | 0.03% | 1.02% | 0.42% | 0.42% | 0.26% | 0.39% | 0.00% |
Crinetics Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $12.28M, based on 6 Wall Street analysts, with a range of $5.75M to $19.18M. The forecast indicates a -8.00% fall compared to CRNX last annual SG&A of $13.34M (Jun 23).
Crinetics Pharmaceuticals EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 7 | 4 | 3 | 13 | 15 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.94 | $-0.82 | $-0.79 | $-0.75 | $-0.79 | $-0.74 | $-0.71 | $-0.60 | $-0.60 | $-0.51 | $-0.37 | $-0.25 |
| Avg Forecast | $-1.15 | $-1.15 | $-1.15 | $-1.13 | $-1.07 | $-1.06 | $-1.00 | $-0.96 | $-0.93 | $-0.91 | $-0.86 | $-0.81 | $-0.86 | $-0.87 | $-0.83 | $-0.82 | $-0.78 | $-0.64 | $-0.58 | $-0.63 | $-0.68 | $-0.57 | $-0.46 | $-0.41 | $-1.65 |
| High Forecast | $-1.15 | $-1.15 | $-1.15 | $-1.13 | $-1.07 | $-1.06 | $-1.00 | $-0.96 | $-0.93 | $-0.85 | $-0.86 | $-0.81 | $-0.79 | $-0.87 | $-0.83 | $-0.82 | $-0.78 | $-0.41 | $-0.37 | $-0.40 | $-0.43 | $-0.36 | $-0.29 | $-0.26 | $-1.32 |
| Low Forecast | $-1.15 | $-1.15 | $-1.15 | $-1.13 | $-1.07 | $-1.06 | $-1.00 | $-0.96 | $-0.93 | $-0.96 | $-0.86 | $-0.81 | $-0.97 | $-0.87 | $-0.83 | $-0.82 | $-0.78 | $-0.86 | $-0.78 | $-0.85 | $-0.91 | $-0.76 | $-0.61 | $-0.55 | $-1.98 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.09% | 0.99% | 0.96% | 0.96% | 1.23% | 1.28% | 1.13% | 0.89% | 1.06% | 1.12% | 0.90% | 0.15% |
According to undefined Wall Street analysts, Crinetics Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CRNX previous annual EPS of $NaN (undefined).
Crinetics Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KZR | Kezar Life Sciences | $0.57 | $17.50 | 2970.18% | Buy |
| KRON | Kronos Bio | $0.95 | $7.63 | 703.16% | Buy |
| LYEL | Lyell Immunopharma | $1.23 | $9.50 | 672.36% | Hold |
| PASG | Passage Bio | $0.81 | $6.00 | 640.74% | Buy |
| RGNX | REGENXBIO | $12.84 | $38.00 | 195.95% | Buy |
| BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
| GPCR | Structure Therapeutics | $40.84 | $86.00 | 110.58% | Buy |
| VRDN | Viridian Therapeutics | $22.06 | $37.83 | 71.49% | Buy |
| MRUS | Merus | $50.14 | $77.86 | 55.29% | Buy |
| CYTK | Cytokinetics | $55.88 | $80.92 | 44.81% | Buy |
| CRNX | Crinetics Pharmaceuticals | $53.80 | $70.14 | 30.37% | Buy |
CRNX Forecast FAQ
Is Crinetics Pharmaceuticals a good buy?
Yes, according to 6 Wall Street analysts, Crinetics Pharmaceuticals (CRNX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of CRNX's total ratings.
What is CRNX's price target?
Crinetics Pharmaceuticals (CRNX) average price target is $70.14 with a range of $39 to $97, implying a 30.37% from its last price of $53.8. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Crinetics Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for CRNX stock, the company can go up by 30.37% (from the last price of $53.8 to the average price target of $70.14), up by 80.30% based on the highest stock price target, and down by -27.51% based on the lowest stock price target.
Can Crinetics Pharmaceuticals stock reach $80?
CRNX's highest twelve months analyst stock price target of $97 supports the claim that Crinetics Pharmaceuticals can reach $80 in the near future.
What are Crinetics Pharmaceuticals's analysts' financial forecasts?
Crinetics Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $5.23M (high $5.23M, low $5.23M), average EBITDA is $-5.229M (high $-5.229M, low $-5.229M), average net income is $-322M (high $-322M, low $-322M), average SG&A $325.67M (high $325.67M, low $325.67M), and average EPS is $-4.079 (high $-4.079, low $-4.079). CRNX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $39.5M (high $39.5M, low $39.5M), average EBITDA is $-39.5M (high $-39.5M, low $-39.5M), average net income is $-362M (high $-362M, low $-362M), average SG&A $2.46B (high $2.46B, low $2.46B), and average EPS is $-4.58 (high $-4.58, low $-4.58).
Did the CRNX's actual financial results beat the analysts' financial forecasts?
Based on Crinetics Pharmaceuticals's last annual report (Dec 2022), the company's revenue was $4.74M, which missed the average analysts forecast of $6.3M by -24.81%. Apple's EBITDA was $-168M, beating the average prediction of $-26.451M by 534.70%. The company's net income was $-160M, missing the average estimation of $-203M by -21.34%. Apple's SG&A was $42.39M, missing the average forecast of $392.36M by -89.20%. Lastly, the company's EPS was $-3.08, beating the average prediction of $-2.829 by 8.88%. In terms of the last quarterly report (Jun 2023), Crinetics Pharmaceuticals's revenue was $988K, missing the average analysts' forecast of $1.1M by -9.94%. The company's EBITDA was $-52.715M, beating the average prediction of $-1.097M by 4705.38%. Crinetics Pharmaceuticals's net income was $-50.979M, missing the average estimation of $-68.386M by -25.45%. The company's SG&A was $13.34M, missing the average forecast of $68.32M by -80.47%. Lastly, the company's EPS was $-0.94, beating the average prediction of $-0.866 by 8.60%